Serologicals Implements Rule 10b5-1 Stock Trading Program.Business Editors/Health/Medical Writers BIOWIRE2K ATLANTA--(BUSINESS WIRE)--March 16, 2004 Serologicals Corporation (Nasdaq/NM: SERO SERO Southeast Regional Office SERO Sekundaerrohstoffe (recycling, former GDR) SERO Syringe Exchange Resources Online SERO System Engineering/Engineer Release Order SERO Site Emergency Response Organisation (nuclear) ) announced today that it has implemented a stock trading program in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The program permits participating Company executives and Board members to adopt pre-arranged stock trading plans to sell a portion of their Company stock over time. Rule 10b5-1 allows officers and directors to adopt written, pre-arranged stock trading plans when they do not have material, non-public information. Once the plans are adopted, the officers or directors have no discretion over the timing or price of the sales. These plans enable officers and directors to gradually diversify their investment portfolios, spread stock trades out over an extended period of time to reduce any market impact, and avoid concerns over whether they had material, non-public information when their stock was traded. Desmond H. O'Connell, Jr., the Chairman of the Company's Board of Directors, has established a stock trading plan under rule 10b5-1. The plan provides for sales of the Company's stock to be spread out over the next 24 months. Mr. O'Connell will sell stock that he obtains from the exercise of options that, unless exercised, will expire within the next 24 months. Other officers and directors of the Company may adopt 10b5-1 plans in the future. About Serologicals Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. The Company's products and technologies are used in a wide variety of innovative applications within the areas of oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. , hematology hematology Branch of medicine concerned with the nature, function, and diseases of the blood. It covers the cellular and serum composition of blood, the coagulation process, blood-cell formation, hemoglobin synthesis, and disorders of all these. , immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic , cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. and infectious diseases infectious diseases: see communicable diseases. , as well as in the study of molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller . Serologicals has more than 650 employees worldwide, and its stock is traded on the Nasdaq National Stock Market under the symbol SERO. Serologicals is a registered trademark of Serologicals Royalty Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion